EBITDA: Income before interest, taxes, depreciation and amortization.
Werewolf Therapeutics, Inc. (HOWL) had EBITDA of $-59.04M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-60.82M |
|
-- |
|
-- |
|
$60.68M |
|
$-60.68M |
|
$-0.14M |
|
$-60.82M |
|
$-60.82M |
|
$-60.82M |
|
$-60.82M |
|
$-60.82M |
|
$-60.82M |
|
$-60.68M |
|
|
EBITDA |
$-59.04M |
46.02M |
|
46.81M |
|
$-1.32 |
|
$-1.33 |
|
| Balance Sheet Financials | |
$58.59M |
|
$4.69M |
|
$10.81M |
|
$69.40M |
|
$36.15M |
|
-- |
|
$8.44M |
|
$44.59M |
|
$24.80M |
|
$24.80M |
|
$24.80M |
|
48.60M |
|
| Cash Flow Statement Financials | |
$-60.29M |
|
-- |
|
$6.03M |
|
$112.22M |
|
$57.95M |
|
$-54.26M |
|
$6.25M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.62 |
|
-- |
|
-- |
|
-- |
|
1.14 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-60.29M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-245.20% |
|
-245.20% |
|
-87.64% |
|
-245.20% |
|
$0.51 |
|
$-1.29 |
|
$-1.29 |
|